Cysteine proteinase inhibitors stefin A and stefin B in operable carcinoma of the head and neck

Abstract

Purpose. To evaluate the significance of cysteine proteinase inhibitors stefins (Stefs) A and B for a treatment decision and prognosis in operable squamous cell carcinoma of the head and neck (SCCHN).

Patients and methods. Stefs A and B concentrations were determined immunobiochemically using ELISAs in cytosols prepared from the tumor and adjacent normal mucosa from 91 patients with operable SCCHN. The median follow-up period of patients alive at the close-out date was 5.8 years (range, 5-9.3 years).

Results. Stef A concentrations were significantly higher in tumor compared to normal mucosa (P=0.05). When a subgroup with clinically palpable node(s) at presentation was taken into consideration (n = 57), a significant difference in Stef A (P = 0.03) and Stef B (P = 0.02) concentrations between those with negative and positive necks, as determined on histopathological examination, was observed. On the univariate survival analysis, higher Stefs’ concentrations turned to be prognostically advantageous. Stef A proved its independent prognostic significance also on multivariate setting.

Conclusions. With the capability to differentiate between the pN0- and pN+-stages of the disease in the patients originally presented as node-positive, Stefs A and B could be useful markers when deciding on the extent of neck surgery. In addition, both Stefs proved to be reliable prognosticators for survival in patients with operable SCCHN.